According to registration data on stock exchanges, the first share sale of Supriya Lifescience Limited was registered 5.69 times on the second day of issuance. According to NSE data, the initial public offering (IPO) received bids of 8,27,05,698 shares compared with 1,45,28,299 shares offered.
On Friday, the retail retail investor (RII) portfolio was registered 25.38 times – the highest of the three investor groups. The section dedicated to non-institutional investors was registered 2.90 times and the section dedicated to Qualified Institutional Buyers (QIBs) was registered 53% today.
The IPO consists of a new issue of up to Rs 200 crore and an offer to sell up to Rs 500. The company is selling shares in the price range of Rs 265-274/equity share. On Wednesday, the company raised Rs 315 crore from anchor investors.
The issue was registered 2.33 times on the first day of release. Proceeds from the new issue will be used to finance capital expenditure requirements, debt repayment, and general corporate purposes. ICICI Securities and Axis Capital are the curators of this offer.
Supriya Lifescience is one of India’s major manufacturers and suppliers of active pharmaceutical ingredients (APIs), with a focus on research and development. As of March 2021, the company manufactures 38 APIs focusing on diverse therapeutic segments such as antihistamines, analgesics, anesthetics, vitamins, anti-asthmatics and anti-allergics.
The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India during the financial years 2016-2017 and 2020-2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in fiscal 2020-21 in terms of volume.
https://www.ndtv.com/business/supriya-lifescience-ipo-subscription-news-supriya-lifescience-ipo-subscribed-5-69-times-on-second-day-of-issue-2657215 Supriya Lifescience IPO registered 5.69 times on the second day of release